Immuno-oncology for surgeons
Immuno-oncology for surgeons
Cancer has traditionally been treated with surgery, cytotoxic chemotherapy and/or radiotherapy. The focus of treatment has been the mutated neoplastic cell. Critical advances in genomic and molecular techniques herald the potential for personalized treatments. Incremental breakthroughs in immunology have translated to a step‐change in care by providing a mechanistic understanding of the immune system and how it may be mobilized to target cancer cells. As a result, clinical trials of immune‐modifying agents have increased at an exponential rate and are revolutionizing cancer care. It is increasingly likely that the surgical oncologist will find themself caring for patients who have had immuno‐oncology therapies as part of their neoadjuvant or adjuvant treatment. This review provides an update on immuno‐oncology for the surgeon, covering the mechanisms of action of the agents in use. Emerging and surgically relevant toxicities are discussed, and available data on combining and sequencing cancer surgery with immuno‐oncology treatments are summarized.
Antibodies, Monoclonal, Humanized/therapeutic use, Antineoplastic Agents, Immunological/therapeutic use, CD8-Positive T-Lymphocytes/physiology, Dendritic Cells/immunology, Forecasting, Humans, Immunocompetence/physiology, Immunotherapy/adverse effects, Medical Oncology/methods, Neoplasms/immunology, Patient Safety, Surgical Procedures, Operative/adverse effects, Tumor Escape/immunology, Tumor Microenvironment/immunology
1273-1282
Lee, S.L.
73132638-fb25-413d-9a81-6040c37eb2c3
Al-Shamkhani, A.
0a40b3ce-9d71-4d41-9369-7212f0a84504
Mirnezami, A.
b3c7aee7-46a4-404c-bfe3-f72388e0bc94
September 2019
Lee, S.L.
73132638-fb25-413d-9a81-6040c37eb2c3
Al-Shamkhani, A.
0a40b3ce-9d71-4d41-9369-7212f0a84504
Mirnezami, A.
b3c7aee7-46a4-404c-bfe3-f72388e0bc94
Lee, S.L., Al-Shamkhani, A. and Mirnezami, A.
(2019)
Immuno-oncology for surgeons.
British Journal of Surgery, 106 (10), .
(doi:10.1002/bjs.11224).
Abstract
Cancer has traditionally been treated with surgery, cytotoxic chemotherapy and/or radiotherapy. The focus of treatment has been the mutated neoplastic cell. Critical advances in genomic and molecular techniques herald the potential for personalized treatments. Incremental breakthroughs in immunology have translated to a step‐change in care by providing a mechanistic understanding of the immune system and how it may be mobilized to target cancer cells. As a result, clinical trials of immune‐modifying agents have increased at an exponential rate and are revolutionizing cancer care. It is increasingly likely that the surgical oncologist will find themself caring for patients who have had immuno‐oncology therapies as part of their neoadjuvant or adjuvant treatment. This review provides an update on immuno‐oncology for the surgeon, covering the mechanisms of action of the agents in use. Emerging and surgically relevant toxicities are discussed, and available data on combining and sequencing cancer surgery with immuno‐oncology treatments are summarized.
Text
IO for Surgeons SLL AHM AAS
- Accepted Manuscript
More information
Accepted/In Press date: 4 April 2019
e-pub ahead of print date: 18 July 2019
Published date: September 2019
Keywords:
Antibodies, Monoclonal, Humanized/therapeutic use, Antineoplastic Agents, Immunological/therapeutic use, CD8-Positive T-Lymphocytes/physiology, Dendritic Cells/immunology, Forecasting, Humans, Immunocompetence/physiology, Immunotherapy/adverse effects, Medical Oncology/methods, Neoplasms/immunology, Patient Safety, Surgical Procedures, Operative/adverse effects, Tumor Escape/immunology, Tumor Microenvironment/immunology
Identifiers
Local EPrints ID: 433104
URI: http://eprints.soton.ac.uk/id/eprint/433104
ISSN: 0007-1323
PURE UUID: 1d1dd1c5-3d53-44b8-9621-0eadcff4e2ea
Catalogue record
Date deposited: 08 Aug 2019 16:30
Last modified: 17 Mar 2024 02:47
Export record
Altmetrics
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
